View ValuationRibbon Acquisition 将来の成長Future 基準チェック /06現在、 Ribbon Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長12.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jul 02New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Negative equity (-US$355k). High level of non-cash earnings (1,727% accrual ratio). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$51.6m market cap).New Risk • Apr 09New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$344k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$344k). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Large one-off items impacting financial results. Market cap is less than US$100m (US$50.4m market cap).New Risk • Apr 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$63.7m market cap).お知らせ • Jul 02DR.C Medical Medicine Co., Ltd. entered into a business combination agreement to acquire Ribbon Acquisition Corp. (NasdaqCM:RIBB) in a reverse merger transaction for approximately $350 million.DR.C Medical Medicine Co., Ltd. entered into a business combination agreement to acquire Ribbon Acquisition Corp. (NasdaqCM:RIBB) in a reverse merger transaction for approximately $350 million on June 30, 2025. Current DR.C Medical Medicine Co., Ltd. shareholders will retain 100% of their equity and will continue to own approximately 82.91% of the combined company on a pro forma basis, assuming no redemptions by Ribbon Acquisition Corp shareholder. Combined company to have an implied initial pro forma equity value of approximately $422.15 Million, assuming no redemptions and the transaction is expected to deliver cash proceeds of around $50.42 Million to DR.C Medical Medicine Co., Ltd. assuming no redemptions to fund DR.C Medical Medicine Co., Ltd. business and operations, which include devices’ clinical trial and certification. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Ribbon Acquisition Corp. Geneva Capital Group acted as financial advisor for DR.C Medical Medicine Co., Ltd. The Ross Law Group, LLC acted as legal advisor for DR.C Medical Medicine Co., Ltd. Celine & Partners, PLLC acted as legal advisor for Ribbon Acquisition Corp.お知らせ • Apr 03Ribbon Acquisition Corp. announced delayed annual 10-K filingOn 04/01/2025, Ribbon Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ribbon Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:RIBB - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A1-1-1N/A12/31/2025N/A1-1-1N/Aアナリストによる今後の成長予測収入対貯蓄率: RIBBの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RIBBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RIBBの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RIBBの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RIBBの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RIBBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 18:39終値2026/06/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ribbon Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 02New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Negative equity (-US$355k). High level of non-cash earnings (1,727% accrual ratio). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$51.6m market cap).
New Risk • Apr 09New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$344k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$344k). Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Large one-off items impacting financial results. Market cap is less than US$100m (US$50.4m market cap).
New Risk • Apr 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$63.7m market cap).
お知らせ • Jul 02DR.C Medical Medicine Co., Ltd. entered into a business combination agreement to acquire Ribbon Acquisition Corp. (NasdaqCM:RIBB) in a reverse merger transaction for approximately $350 million.DR.C Medical Medicine Co., Ltd. entered into a business combination agreement to acquire Ribbon Acquisition Corp. (NasdaqCM:RIBB) in a reverse merger transaction for approximately $350 million on June 30, 2025. Current DR.C Medical Medicine Co., Ltd. shareholders will retain 100% of their equity and will continue to own approximately 82.91% of the combined company on a pro forma basis, assuming no redemptions by Ribbon Acquisition Corp shareholder. Combined company to have an implied initial pro forma equity value of approximately $422.15 Million, assuming no redemptions and the transaction is expected to deliver cash proceeds of around $50.42 Million to DR.C Medical Medicine Co., Ltd. assuming no redemptions to fund DR.C Medical Medicine Co., Ltd. business and operations, which include devices’ clinical trial and certification. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Ribbon Acquisition Corp. Geneva Capital Group acted as financial advisor for DR.C Medical Medicine Co., Ltd. The Ross Law Group, LLC acted as legal advisor for DR.C Medical Medicine Co., Ltd. Celine & Partners, PLLC acted as legal advisor for Ribbon Acquisition Corp.
お知らせ • Apr 03Ribbon Acquisition Corp. announced delayed annual 10-K filingOn 04/01/2025, Ribbon Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.